Grupo Fleury achieved a gross revenue of R$ 2.0 billion in 4Q24, an 8.7% increase over 4Q23, with EBITDA reaching R$ 405.5 million (22.0% margin) and Net Income of R$ 84.0 million. The company demonstrated consistent performance across its segments, with significant growth in mobile services and B2B diagnostic medicine, while maintaining a solid financial structure with reduced leverage.
Gross Revenue reached R$ 1,994.3 million in 4Q24, an 8.7% increase compared to 4Q23.
EBITDA for 4Q24 was R$ 405.5 million, with a margin of 22.0%, showing a 7.9% growth over 4Q23.
Net Income for 4Q24 stood at R$ 84.0 million, a 3.3% increase from 4Q23, with a net margin of 4.6%.
The company's leverage decreased to 1.0x Net Debt/EBITDA by the end of 2024, down from 1.2x in 2023.
The company did not provide specific forward-looking financial guidance for 2025. However, it emphasized its commitment to disciplined capital allocation, continued evaluation of strategic opportunities, and strengthening its position as a leading healthcare provider in Brazil through integrated and sustainable solutions.
Analyze how earnings announcements historically affect stock price performance